R&D channel feed

Biden awards $24M to de­vel­op mR­NA tech tar­get­ing can­cer, oth­er dis­eases

Last year
Pharma
FDA+

J&J to close its Lei­den vac­cine unit fol­low­ing wider in­fec­tious dis­ease cuts

Last year

Agenus to trim its staff num­bers and as­sets

Last year
People

Pfiz­er ex­pects few­er peo­ple need­ed for Ly­me dis­ease vac­cine tri­al

Last year
Pharma

Roche posts in­ter­im OS da­ta from PhI­II TIG­IT tri­al af­ter leak — and an­a­lysts say it bodes well for fi­nal read­out

Last year

Ex­clu­sive: As­traZeneca and Vaxess de­vel­op­ing skin patch mR­NA vac­cines for pan­dem­ic flu

Last year
Deals

Apel­lis' safe­ty probe in­to eye drug un­earths is­sues with in­jec­tion kits, while side ef­fects re­main 'very rare'

Last year
Pharma

Ful­crum’s sick­le cell hold re­solved, and tri­al will now fo­cus on more se­vere pa­tients

Last year
FDA+

La­va Ther­a­peu­tics makes cuts to its head­count

Last year
People

In­ovio spin­out plans piv­otal study for can­cer vac­cine as it touts al­ter­na­tive take on PhIb/IIa liv­er can­cer da­ta

Last year

Ar­a­vive warns of pos­si­ble liq­ui­da­tion as it ax­es all clin­i­cal work, lays off 70% of em­ploy­ees

Last year
People

Leo Phar­ma spend­ing $14M up­front to ac­quire Tim­ber

Last year
Deals

FDA puts par­tial hold on Gilead’s CD47 hope­ful in AML

Last year
FDA+

An­dreessen Horowitz-backed start­up lands $200M for AI-based drug dis­cov­ery

Last year
Financing
AI

Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Last year
Pharma

Mod­er­na's up­dat­ed Covid vac­cine like­ly pro­vides pro­tec­tion against new vari­ants, but up­take re­mains un­cer­tain

Last year

Cis­platin, car­bo­platin short­ages raise ques­tions about im­pact on clin­i­cal tri­als 

Last year

No­var­tis lays out San­doz spin­off time­line with an Oct. 4 tar­get date af­ter share­hold­er vote

Last year

AB­VC Bio­Phar­ma to break ground in Chi­na, ad­vances 20% stake in Zhonghui re­al es­tate 

Last year
China

Fed­er­al court judge rules in fa­vor of Ot­suka's Tai­ho in Lon­surf patent suit

Last year

In­tel­lia, Verve run clin­i­cal tri­als abroad amid FDA’s ‘cau­tious’ ap­proach to gene edit­ing

Last year

Se­lec­ta Bio­sciences is nar­row­ing its fo­cus

Last year

I-Mab to seek ap­proval of pe­di­atric growth hor­mone de­fi­cien­cy drug in Chi­na next year af­ter PhI­II win

Last year

SPAC Ash­ing­ton In­no­va­tion plans to ac­quire dor­mant biotech Celixir and lead heart fail­ure pro­gram for $172M

Last year
Deals
First page Previous page 74757677787980 Next page Last page
A service from the Financial Times